FluoroPharma Medical discovers and develops positron emission tomography (PET) imaging products to detect and asses diseases early, accurately and at the cellular and molecular levels. FluoroPharma’s is focused on developing breakthrough PET imaging agents and is advancing two products in clinical trials for assessing acute and chronic forms of coronary artery disease. Other products in development include agents for detecting inflamed atherosclerotic plaque in peripheral arteries and that could potentially image specific cancers and brain tissue affected by Alzheimer’s diseases. For more information, visit the company’s website at www.fluoropharma.com.